Swiss drug manufacturer Novartis MS pill approval is making a big splash in the medical community. The new MS pill offers patients an easier, more convenient way to get their treatment without having to leave their home. And doctors say this means more patients will continue their treatment over the long term. Consensus has always been that the bottom line for any MS therapy to be successful is for the patient to stay on that therapy over the long-haul.  MS afflicts about 400,000 in the U.S. alone. There is no cure yet for the disease, but there have been advances in both reducing relapse frequencies and in modifying the course of the MS.  But one problem is that patients often have symptoms so severe that they become depressed or debilitated to the point that it makes it difficult for them to get out of the house, or they simply don’t …